Lubrizol invests $60m in drug production at Particle Science plant
The Lubrizol Corporation has invested $60m (€53m) in its Particle Science drug manufacturing business.
Lubrizol said the investment - which be used to add extra manufacturing space at its facility in Bethlehem, Pennsylvania – will strengthen its excipient production, drug formulation and medical device businesses.
The expanded unit is expected to be operational in the fourth quarter.
Lubrizol - which has been owned by acquired by Warren Buffett’s Berkshire Hathaway group since 2011 – acquired Particle Sciences in 2015.
